Mitsubishi UFJ Trust & Banking Corp Purchases 75,982 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mitsubishi UFJ Trust & Banking Corp lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 578,265 shares of the company’s stock after buying an additional 75,982 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Teva Pharmaceutical Industries were worth $12,745,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in TEVA. Janus Henderson Group PLC grew its stake in Teva Pharmaceutical Industries by 7,945.2% in the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after acquiring an additional 4,732,374 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its position in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the period. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $58,243,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Teva Pharmaceutical Industries by 237.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock valued at $60,863,000 after buying an additional 2,376,668 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after buying an additional 1,778,268 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 2.8 %

NYSE:TEVA opened at $15.06 on Friday. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The firm has a market capitalization of $17.07 billion, a price-to-earnings ratio of -10.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock’s 50 day moving average price is $17.21 and its two-hundred day moving average price is $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TEVA shares. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.